Randox Health Grand National Family Fun Day launched at The Cope

Randox Health Grand National Family Fun Day launched at The Cope

RTÉ Raidió na Gaeltachta show Barrscéalta, together with Randox Health, would like to invite the public to join them for a special live show from The Cope in Dungloe at 11 am on Friday 16th February, to launch the upcoming Randox Health Grand National Family Fun Day.

To celebrate their sponsorship of the Grand National, Randox Health has offered Barrscéalta a superb prize of a trip for two to the event, to include flights and accommodation, and entry to the Randox Health Grand National.  Listeners can enter the competition by text in the week running up to the show from Dungloe – tune in to RnaG for full details – and all those who turn up for the live programme can also enter on the day to be in with a chance to win.  The winner will be drawn during the show.

Dr Peter FitzGerald, Randox Managing Director, commented;

“We are delighted to offer this prize to one lucky listener, in recognition of the consistent support Randox Teoranta has received from the local community since our establishment in Donegal in 2008.”

 “Our aim to offer world-leading science, engineering and software careers in west Donegal, so that people working in these fields no longer have to move away from home to find work, has been incredibly well-received. We’re therefore delighted that we’ll have representatives from Dungloe join us at the Randox Health Grand National as we celebrate together how far we have come.”

On Friday 16th February, there will also be lots of spot prizes for members of the audience, and plenty of tea, coffee and traybakes, supplied by The Cope.  The brand new Randox Health Grand National trophy, which will be unveiled to the public for the first time on 13th February at the prestigious Weights Event in London, will be on display during the programme. The new trophy, designed and created by renowned Liverpool silversmith Shannon O’Neill, stands 45 cm high and is made of solid silver gilded with gold.

Speaking of the trophy, Dr FitzGerald said;

“There is no other race in the world like the Randox Health Grand National, and we want to ensure that the trophy reflects the status of the achievement.”

The Randox Health Grand National Family Day will take place in Randox Teoranta, Meenmore, on the 14th April from 1 pm – 6 pm.  It’s a free event for all the family, with plenty of entertainment for kids, including a bouncy castle, as well as food and drink, live music and dance, craft stalls and a large screen for the public to watch the big races over at Aintree.  RTÉ Raidió na Gaeltachta’s sports programme Spórt an tSathairn, presented by Seán Bán Breathnach, will be broadcasting live from the event on 14th April.

Áine Ní Churráin will present this special edition of Barrscéalta on RTÉ Raidió na Gaeltachta live from The Cope on Friday 16th February.  All are welcome to attend the event which will take place between 11 am and 12 pm. There is no need to book.

For further information please contact the Randox PR Team: phone 028 9442 2413 or email randoxpr@randox.com 

 

Photography credit The Goldsmiths Company Assay Office.


Drug and Alcohol Testing in the Medico-legal Market

Medico-legal testing for drugs and alcohol may be required by various professional bodies involved in child custody cases, care proceedings or child protection cases. In cases regarding divorce and children, a dispute may arise during the process of discussions involving the custody of children. In these cases drug and alcohol testing may be sought if there has been a substance abuse claim against a parent fighting for custody or visitation. In cases relating to child protection, social services may seek drug and alcohol testing if child welfare claims have been made regarding suspected substance misuse.

Normally in medico-legal cases a hair sample would be tested as it provides the longest detection window.

 

Why is Drug and Alcohol Testing in Medico-legal Cases Important?

Drug and alcohol testing is important to ensure child protection from the detrimental effects of parental substance misuse and to ensure they have a quality of life they deserve. In addition it is also important to enable parents the opportunity to get the help and support they need and begin rehabilitation treatment.

Doing the right thing by the child is the main priority, and where possible parent and child relationships are sought to be maintained. Drug and alcohol testing assists in these efforts and in such cases abstinence monitoring testing may be required to assess a parent’s recovery e.g. if a visitation case is being reassessed.

 

Our Expertise

At Randox Testing Services we provide drug and alcohol testing to all professionals within the family law and medico-legal sector. Our hair drug testing service utilises accredited testing methods and is made more cost-effective through utilising patented testing methods developed by Randox.

We understand the impact a positive result can have on a parent, child, and extended family and ensure results of the highest precision and accuracy. With over 35 years’ experience in the diagnostic industry we have gained reputation as a trusted provider.

Our drug and alcohol testing solutions are flexible and can be tailored to our customer needs with a choice of testing methods. We offer a comprehensive drugs of abuse test menu and our service also includes expert witness reporting where applicable.

 

Contact Us

To speak to one of our experts about hair drug testing contact enquiries@randoxtesting.com or call +44 (0) 161 741 2760. We work with companies within the medico-legal sector along with a wide range of workplaces and also private individuals.

For further information on RTS, or to arrange interviews, please contact the Randox PR team via email: randoxpr@randox.com or phone 028 9442 2413


Randox Laboratories and Qnostics announce strategic partnership

Randox Laboratories and Qnostics have today announced that they have entered into a strategic partnership.  The partnership will provide Randox Laboratories with access to the Qnostics molecular range of products for sales and distribution purposes, complementing the established Randox Laboratories portfolio.

Access to the Randox Laboratories commercial capabilities will enhance Qnostics’ market penetration, whilst also maintaining their presence as an independent provider of molecular quality controls and custom services.

MD of Randox Laboratories, Dr Peter FitzGerald said;

“We are delighted to have agreed a strategic partnership with Qnostics, an arrangement we see as mutually beneficial.  We look forward to working together to strengthen the molecular service we provide to our global markets whilst enhancing the Qnostic brand and market penetration.”

Dr Frank Opdam, Head of Commercial of Qnostics said;

“We believe this is an ideal partnership. We look forward to working with Randox Laboratories and the growth that will result from the global access this partnership will provide to Qnostics for its expanding range of molecular quality control products.”

For further information please contact the Randox PR Team: phone 028 9442 2413 or email randoxpr@randox.com 


The Complete Solution to Cardiac Risk Assessment

“CVDs are the number 1 cause of death globally: more people die annually from CVDs than from any other cause”.  In 2015, roughly 17.7 million people died from CVD, representing 31% of all global deaths: 7.4 million were due to coronary heart disease and 6.7 million were due to stroke. (WHO, 2017)

 

Cardiac health and regular cardiovascular screening is important to enable risk factors to be detected in their earliest stages.  There are a few factors which contribute to CVD.  These include: smoking, unhealthy diet, excessive alcohol consumption, low physical activity levels.  Whilst there are only a few factors contributing to CVD, these can be maintained by the patient through living a healthy lifestyle including: quitting smoking, consuming no more than the recommended allowance of alcohol, cutting out junk food, and exercising for 30 minutes a day, 3 – 5 days a week.  In a perfect world, this would be easy and CVD would not be a global problem.  However, due to busy lifestyles, cravings, reduced willpower, and convenience, not all individuals in today’s world will be able to avoid CVDs.  Therefore, it is vitally important that individuals are tested for CVDs to detect them in the earliest stages to reduce damage, prevent further damage, or even death.  Furthermore, many individuals suffer from inherited cardiac risk factors, which stresses the need for accurate testing of both traditional and novel cardiac risk biomarkers.

 

Randox offer the complete solution to cardiac risk assessment including: RX analysers, traditional and novel reagents, internal quality control (Acusera), and external quality control (RIQAS).

 

RX Series

Randox has developed the RX series range of clinical chemistry analysers for high-quality semi-automated and fully automated testing. Choose between the RX misano, RX monaco, RX daytona+, RX imola, and the RX modena depending on the throughput of your laboratory. The RX series offers a suitable analyser for your laboratory’s needs.  For more information on the Randox RX series, please click here or email therxseries@randox.com

 

Reagents

As previously mentioned, early assessment of cardiac risk is vital. Randox offer a range of novel risk biomarkers for both very early and the genetic assessment of cardiac risk.

The niche Adiponectin assay allows for the early assessment of CVD.  Adiponectin levels are inversely correlated with abdominal visceral fat which has proven to be a strong predictor of T2DM.  Body-Mass Index (BMI) is a common method for determining which patients are classified as underweight, healthy, overweight or obese, however, BMI does not take into account gender, ethnicity or activity levels.  For example, measuring the BMI of athletes who have a high BMI due to muscle weighing heavier than fat would classify them as obese which is inaccurate.  Measuring adiponectin levels is therefore a much more reliable indicator of at-risk patients compared to BMI.

LDL cholesterol is often referred to as the ‘bad cholesterol’.  High concentrations of LDL-cholesterol is considered to be the most important clinical predictor, of all single parameters, with respect to coronary atherosclerosis.  However, sLDL is a smaller, more dense subfraction of LDL-cholesterol.   sLDL particles more readily permeate the inner arterial wall and are more susceptible to oxidation.  Individuals with a predominance of sLDL have a 3-fold increased risk of myocardial infarction.  Measurement of sLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly.

Elevated levels of Lp(a) are considered to be both a casual risk factor and independent genetic marker of atherosclerotic disorders.  The major challenge associated with Lp(a) measurement is the size variation of apo(a) within Lp(a).  Dependent upon the size of apo(a) in the assay calibrator, many assays under or overestimate apo(a) size in the patient sample.  Numerous commercially available products suffer apo(a) size related bias, resulting in an over estimation of Lp(a) in samples with large apo(a)molecules and an under estimation in samples with small apo(a) molecules.  The antibody used in the Randox method detects the complete Lp(a) molecule providing accurate and consistent results.  This was proven by the IFCC who developed a gold standard ELISA reference assay and compared 22 commercially available tests.  The Randox Lp(a) method displayed the least (minimal) amount of apo(a) size related bias, proving it be a superior offering.

HDL3 Cholesterol is a smaller and more dense subfraction of the HDL particle.  HDL is the scavenger of cholesterol within arterial walls and the levels of HDL3 is too low, the ability to remove this cholesterol is reduced.  Therefore, it is widely accepted that there is an inverse correlation between HDL3 and CVD risk.

Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers.  Contact us to enquire about your specific analyser.

For more information on Randox Reagents, please click here or email reagents@randox.com

 

Acusera – Internal Quality Control

The Acusera cardiac controls have been designed to cover a wide range of cardiac markers at clinical decision levels, eliminating the extra expense of an additional low level control.  The controls are available in a both liquid ready-to-use and lyophilized formats making them ideal for all situations and manufactured from 100% human serum a matrix similar to that of the patient is guaranteed.  For more information on the Randox Acusera internal quality control, please click here or email acusera@randox.com

 

RIQAS – External Quality Control

The RIQAS Liquid Cardiac EQA programme is designed to monitor the performance of up to 9clinically significant cardiac markers including: CK-MB mass, D-dimer, Digoxin, homocysteine, hsCRP, myoglobin, NT proBNP, troponin I, and troponin T.  RIQAS is ISO/IEC 17043 accredited and allows the registration of up to five instruments at no extra cost.  All samples are 100% human serum and provided in a liquid ready-to-use format for enhanced convenience.  Submit your results bi-weekly and view reports online via RIQAS.Net.  For more information on RIQAS, the world’s largest international EQA scheme, please click here or email acusera@randox.com

 

For further information, please contact the Randox PR team via email: randoxpr@randox.com or phone 028 9442 2413

cardiac

 


Simple health checks, sophisticated science at Randox Health

What is health care? When we think of caring for our health, we think of going to the doctor when we feel ill. The healthcare cycle we’re accustomed to is one where we wait for symptoms to present themselves and then we visit a doctor, hoping to be prescribed medication to limit our symptoms.

Is this really health care? Are we really caring for our bodies in the best way possible by waiting for illness to manifest itself? What if we could properly look after our bodies by taking action early to stop illness in its tracks?

The key to this is identifying indicators of pre-illness, and the technology that allows you to do this is now available directly to you through Randox Health.

After investing over £220 million in the invention and production of revolutionary blood-science technology, a single Randox Health check will deliver a complete picture of your health – as it is now and crucially how it is likely to develop in the future.

Randox Health has proven that signs of disease or irregularity can be caught at their earliest stage. This means that, with early action, some cases of illness can even be prevented altogether. Our health checks include, but are not limited to, cancer surveillance, fertility monitoring, heart health, nutrition, digestive and diabetes health.

In other words, from one health check, you’ll receive up to 350 results and afterwards avail of expert advice from the Randox scientists or a Randox Health GP. Not only that, but a complete 12-month programme and repeat testing come as standard so you can have full confidence that you are really taking care of yourself.

Look out for our new ‘Health Made Simple’ blogs beginning next week, where we’ll be delving in to the sophisticated science and diagnostic tests that power each Randox Health check.

You’ll find out about our Everyman, Everywoman and our Signature health checks, as well as our Specialised testing options which focus on specific health issues.

Find out more and start your Randox Health journey today.

For further information, please contact the Randox PR team via email: randoxpr@randox.com or phone 028 9442 2413


Clinical Laboratory Survey